| Literature DB >> 34394226 |
Olutobi Babatope Ojuawo1, Olufemi Olumuyiwa Desalu1, Ademola Emmanuel Fawibe1, Ayotade Boluwatife Ojuawo2, Adeniyi Olatunji Aladesanmi1, Christopher Muyiwa Opeyemi1, Mosunmoluwa Obafemi Adio1, Abdulraheem Olayemi Jimoh3, Dele Ohinoyi Amadu3, Abayomi Fadeyi3, Kazeem Alakija Salami1.
Abstract
BACKGROUND: The optimal management of community acquired pneumonia (CAP) depends on the clinical and microbiological profile in the locality.Entities:
Keywords: Community acquired pneumonia; Nigeria; microbiological profile
Mesh:
Substances:
Year: 2020 PMID: 34394226 PMCID: PMC8351858 DOI: 10.4314/ahs.v20i4.18
Source DB: PubMed Journal: Afr Health Sci ISSN: 1680-6905 Impact factor: 0.927
Socio-demographic characteristics of recruited subjects
| Socio-demographic variables | Frequency (%) |
| ≤20 | 12 (11.8) |
| 21–30 | 15 (14.7) |
| 31–40 | 17 (16.7) |
| 41–50 | 8 (7.8) |
| 51–60 | 12 (11.8) |
| 61–64 | 5 (4.9) |
| ≥ 65 | 34 (33.3) |
| Male | 46 (45.1) |
| Female | 56 (54.9) |
| Yoruba | 98 (96.1) |
| Hausa | 3 (2.9) |
| Igbo | 1 (1.0) |
| Single | 21 (20.6) |
| Married | 67 (65.7) |
| Widowed | 14 (13.7) |
Monthly breakdown of patients recruited
| Month | Frequency (%) |
| January | 5 (4.9) |
| February | 7 (6.9) |
| March | 7 (6.9) |
| April | 8 (7.8) |
| May | 8 (7.8) |
| June | 14 (13.7) |
| July | 13 (12.7) |
| August | 16 (15.7) |
| September | 7 (6.9) |
| October | 7 (6.9) |
| November | 5 (4.9) |
| December | 5 (4.9) |
| Total | 102 (100) |
Frequencies of co-morbidities/risk factors for CAP
| Co-morbidities/risk factors | Frequency (%) |
| Systemic Hypertension | 25 (24.5) |
| Diabetes Mellitus | 11 (10.8) |
| Acid Peptic Disease | 6 (5.9) |
| Connective Tissue Diseases | 2 (2.0) |
| Bronchial Asthma | 3 (2.9) |
| Cigarette Smoking | 11 (10.8) |
| Alcohol Ingestion | 3 (2.9) |
| COPD | 7 (6.9) |
| Congestive Cardiac Failure | 1 (1.0) |
| Cancer | 3 (2.9) |
| HIV | 6 (5.9) |
| Sickle cell disease | 10 (9.8) |
| No comorbidity/risk factor | 14 (13.7) |
Pathogens and mode of isolation
| Organisms and mode of isolation | Frequency (%) |
| 8 (7.8) | |
| 6 (5.9) | |
| 2 (2.0) | |
| 2 (2.0) | |
| 2 (2.0) | |
| 1 (1.0) | |
| 6 (5.9) | |
| 4 (3.9) | |
| 1 (1.0) | |
| 1 (1.0) | |
| 1 (1.0) | |
| 8 (7.8) | |
| 3 (2.9) | |
| 12 (11.8) | |
| 1 (1.0) | |
| 1 (1.0) | |
| 2 (2.0) | |
| 2 (2.0) | |
| 1 (1.0) | |
| 1 (1.0) | |
| 1 (1.0) | |
| 1 (1.0) | |
| 1 (1.0) | |
| 1 (1.0) | |
| 1 (1.0) | |
| 1 (1.0) |
Complications of CAP in recruited subjects
| Complication | Frequency (%) |
| Hypoxaemia | 34 (50.7) |
| Parapneumonic effusion | 9 (13.4) |
| Empyema thoracis | 4 (5.9) |
| Sepsis | 16 (23.9) |
| Lung Abscess | 2 (3.0) |
| Massive haemoptysis | 2 (3.0) |
| Total | 67 (100) |
• Some patients had more than one complication
Drug sensitivity pattern
| Cipro | Ceftria | AmC | Gent | Ceftaz | Imi | Pip/Taz | Azith | Cefurox | |
| 10 | 13 | 10 | 12 | 13 | 16 | NT | 10 | 10 | |
| 5 | 9 | 10 | 9 | 5 | NT | NT | 8 | 9 | |
| 5 | 3 | 7 | 4 | 4 | NT | NT | 6 | 6 | |
| 2 | 1 | 1 | 3 | 3 | 3 | NT | 1 | 1 | |
| 2 | 0 | 0 | 1 | 3 | 3 | 3 | 1 | 0 |
Cipro – Ciprofloxacin, Ceftria – Ceftriaxone, AmC – Amoxicillin/Clavulanic acid, Gent – Gentamicin, Ceftaz – Ceftazidime, Imi – Imipenem, Pip/Taz – Piperacillin Tazobactam, Azi – Azithromycin, CefuroxCefurox – Cefuroxime, NT – Not tested.
Relationship between clinical outcome of patients and their socio-demographic/clinical parameters
| Parameter | Patients alive | Mortalities | Total | Test | p-value |
| 47.60 ± 21.66 | 60.65 ± 21.90 | 0.640 | |||
| Male | 35 (41.2) | 11 (64.7) | 46 (45.1) | 3.168 | 0.075 |
| Female | 50 (58.2) | 6 (35.3) | 56 (54.9) | ||
| Underweight | 8 (9.4) | 2 (11.8) | 10 (9.8) | 1.882 | 0.597 |
| Normal | 56 (65.9) | 8 (47.1) | 64 (62.7) | ||
| Overweight | 19 (22.4) | 1 (5.9) | 20 (19.6) | ||
| Mild Obesity | 1 (1.1) | 0 (0) | 1 (0.9) | ||
| 0–1 | 53 (5.9) | 2 (0) | 55 (4.9) | 14.59 | |
| ≥2 | 32 (56.5) | 15 (23.5) | 47 (51.0) | ||
| Wards | 81 (95.3) | 14 (82.3) | 95 (93.1) | 3.712 | 0.089 |
| ICU | 4 (4.7) | 3 (17.6) | 7 (6.9) | ||
| Yes | 32 (37.6) | 4 (23.5) | 36 (35.3) | 1.236 | 0.266 |
| No | 53 (62.4) | 13 (76.5) | 66 (64.7) | ||
| ≤ 90 | 21 (15.3) | 13 (76.5) | 34 (33.3) | 17.082 | |
| >90 | 64 (75.3) | 4 (3.9) | 68 (66.7) | ||
independent student t-test
chi-square
yates corrected chi-square
fisher's exact test
Relationship between clinical outcome of the patients and their laboratory/radiologic parameters
| Parameter | Patients alive | Mortalities | Total | Test | p-value |
| Yes | 63 (74.1) | 0 (0) | 63 (61.8) | 32.954 | |
| No | 22 (25.9) | 17 (100) | 39 (38.2) | ||
| 1 | 64 (75.2) | 8 (47.1) | 72 (70.6) | 5.440 | |
| ≥2 | 21 (24.7) | 9 (52.9) | 30 (29.4) | ||
| Yes | 12 (14.1) | 4 (23.5) | 16 (15.7) | 0.949 | 0.330 |
| No | 73 (85.9) | 13 (76.5) | 86 (84.3) | ||
| < 4 and >30 | 8 (9.4) | 1 (5.9) | 9 (8.8) | 0.219 | 0.639 |
| 4–30 | 77 (90.6) | 16 (94.1) | 93 (91.1) | ||
| Yes | 60 (70.6) | 11 (64.7) | 71 (69.6) | 0.232 | 0.630 |
| No | 25 (29.4) | 6 (35.3) | 31 (30.4) | ||
| Typical bacteria | 28 (32.9) | 5 (29.4) | 33 (32.4) | 2.263 | 0.943 |
| Typical and atypical | 5 (5.9) | 2 (11.8) | 7 (6.9) | ||
| Typical bacteria and | 5 (5.9) | 1 (5.9) | 6 (5.9) | ||
| Atypical bacteria | 10 (11.4) | 1 (5.9) | 11 (10.8) | ||
| Atypical bacteria | 1 (1.2) | 0 (0) | 1 (0.9) | ||
| Viruses only | 11 (12.9) | 1 (5.9) | 12 (11.8) | ||
| Fungi | 0 (0) | 1 (5.9) | 1 (0.9) | ||
| None | 25 (29.4) | 6 (35.3) | 31 (30.4) |
chi-square
yates corrected chi-square
Multivariate logistic regression to determine the predictors of intra hospital mortality
| Variables | B | p-value | OR | 95% CI |
| Age of patient | 0.015 | 0.486 | 1.015 | 0.973 – 1.059 |
| CURB-65 score – 2 | 2.672 | 14.472 | 1.523 – 137.562 | |
| Involvement of 2 or more lung | 0.170 | 0.814 | 1.185 | 0.286 – 4.909 |
| Presence of | 3.254 | 25.885 | 2.788 – 240.337 | |
| Presence of hypoxaemia | 0.867 | 0.239 | 2.381 | 0.562 – 10.092 |
| Constant | -1.707 | 0.271 | 0.181 |
OR – odds ratio
95% CI – 95% confidence interval